ZT 386

Drug Profile

ZT 386

Alternative Names: ZT-386

Latest Information Update: 10 Nov 2006

Price : $50

At a glance

  • Originator Nippon Zeon; Taisho Pharmaceutical
  • Class Antiasthmatics
  • Mechanism of Action Thromboxane A2 receptor antagonists; Thromboxane synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 10 Nov 2006 Discontinued - Preclinical for Asthma in Japan (unspecified route)
  • 01 Jul 1998 No-Development-Reported for Asthma in Japan (Unknown route)
  • 28 Oct 1994 Preclinical development for Asthma in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top